Elaine Haddock

Dr. Elaine Haddock


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
NDNeeltje van Doremalen
Neeltje van Doremalen
VAVictoria A. Avanzato
Victoria A. Avanzato
KGKerry Goldin
Kerry Goldin
FFFriederike Feldmann
Friederike Feldmann
JSJonathan E. Schulz
Jonathan E. Schulz
VMVincent Munster
Vincent Munster
Nipah virus (NiV) is a highly pathogenic and re-emerging virus, which causes sporadic but severe infections in humans. Currently, no vaccines against NiV have been approved. We previously showed that ChAdOx1 NiV provides full protection against a lethal challenge with NiV Bangladesh (NiV-B) in hamsters. Here, we investigated the efficacy of ChAdOx1 NiV in the lethal African green monkey (AGM) NiV challenge model. AGMs were vaccinated either 4 weeks before challenge (prime vaccination), or 8 and 4 weeks before challenge with ChAdOx1 NiV (prime-boost vaccination). A robust humoral and cellular response was detected starting 14 days post-initial vaccination. Upon challenge, control animals displayed a variety of signs and had to be euthanized between 5 and 7 days post inoculation. In contrast, vaccinated animals showed no signs of disease, and we were unable to detect infectious virus in tissues and all but one swab. No to limited antibodies against fusion protein or nucleoprotein antigen could be detected 42 days post challenge, suggesting that vaccination induced a very robust protective immune response preventing extensive virus replication.

1 September 2020 in Antiviral Research
Verified
Journal Article
Closed access
David HawmanDavid Hawman
David Hawman
EHElaine Haddock
Elaine Haddock
KMKimberly Meade-White
Kimberly Meade-White
GNGlenn Nardone
Glenn Nardone
FFFriederike Feldmann
Friederike Feldmann
HFHeinz Feldmann
Heinz Feldmann

3 December 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
KRKyle Rosenke
Kyle Rosenke
MJMichael A Jarvis
Michael A Jarvis
FFFriederike Feldmann
Friederike Feldmann
BSBenjamin Schwarz
Benjamin Schwarz
AOAtsushi Okumura
Atsushi Okumura
HFHeinz Feldmann
Heinz Feldmann
We remain largely without effective prophylactic/therapeutic interventions for COVID-19. Although many human COVID-19 clinical trials are ongoing, there remains a deficiency of supportive preclinical drug efficacy studies to help guide decisions. Here we assessed the prophylactic/therapeutic efficacy of hydroxychloroquine (HCQ), a drug of interest for COVID-19 management, in 2 animal disease models. The standard human malaria HCQ prophylaxis (6.5 mg/kg given weekly) and treatment (6.5 mg/kg given daily) did not significantly benefit clinical outcome, nor did it reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model. Similarly, when used for prophylaxis or treatment, neither the standard human malaria dose (6.5 mg/kg) nor a high dose (50 mg/kg) of HCQ had any beneficial effect on clinical disease or SARS-CoV-2 kinetics (replication/shedding) in the Syrian hamster disease model. Results from these 2 preclinical animal models may prove helpful in guiding clinical use of HCQ for prophylaxis/treatment of COVID-19.

2 June 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
EHElaine Haddock
Elaine Haddock
FFFriederike Feldmann
Friederike Feldmann
WSW. Lesley Shupert
W. Lesley Shupert
HFHeinz Feldmann
Heinz Feldmann
: The burden on diagnostic and research laboratories to provide reliable inactivation for biological specimens to allow for safe downstream processing is high during the coronavirus disease 2019 (COVID-19) pandemic. We provide safety data regarding commonly used chemical and physical inactivation procedures that verify their effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 April 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
LDLaure R. Deflubé
Laure R. Deflubé
TCTessa N. Cressey
Tessa N. Cressey
Adam HumeAdam Hume
Adam Hume
JOJudith Olejnik
Judith Olejnik
EHElaine Haddock
Elaine Haddock
Elke MühlbergerElke Mühlberger
Elke Mühlberger
Significance: Ebolaviruses belong to the group of nonsegmented negative strand (NNS) RNA viruses. Most members of the Ebolavirus genus cause severe disease in humans. Here, we report that ebolaviruses have evolved a genome replication mechanism that distinguishes them from the other NNS RNA viruses. The ebolavirus replication strategy includes the addition of a nontemplated 3′ nucleotide at the genome ends which may aid in avoiding antiviral recognition. Our data highlight the need for more research on NNS RNA virus replication strategies to reveal commonalities between virus families as well as unique features. Dissecting the replication mechanisms of NNS RNA viruses, including ebolaviruses, paves the way for the development of broad-spectrum antivirals that target the viral replication complexes, thereby preventing virus amplification.

22 November 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
DADanielle Adney
Danielle Adney
JLJamie Lovaglio
Jamie Lovaglio
JSJonathan E. Schulz
Jonathan E. Schulz
CYClaude Kwe Yinda
Claude Kwe Yinda
VAVictoria A. Avanzato
Victoria A. Avanzato
VMVincent Munster
Vincent Munster
An animal model that fully recapitulates severe COVID-19 presentation in humans has been a top priority since the discovery of SARS-CoV-2 in 2019. Although multiple animal models are available for mild to moderate clinical disease, models that develop severe disease are still needed. Mink experimentally infected with SARS-CoV-2 developed severe acute respiratory disease, as evident by clinical respiratory disease, radiological, and histological changes. Virus was detected in nasal, oral, rectal, and fur swabs. Deep sequencing of SARS-CoV-2 from oral swabs and lung tissue samples showed repeated enrichment for a mutation in the gene encoding nonstructural protein 6 in open reading frame 1ab. Together, these data indicate that American mink develop clinical features characteristic of severe COVID-19 and, as such, are uniquely suited to test viral countermeasures.